Success Metrics

Clinical Success Rate

89.5%

Based on 34 completed trials

Completion Rate

89%(34/38)

Active Trials

0(0%)

Results Posted

50%(17 trials)

Terminated

4(10%)

Phase Distribution

Ph phase_3

23%

Ph phase_4

30%

Ph phase_1

Ph not_applicable

Ph phase_2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution35 total trials

Phase 1Safety & dosage

3(8.6%)

Phase 2Efficacy & side effects

8(22.9%)

Phase 3Large-scale testing

9(25.7%)

Phase 4Post-market surveillance

12(34.3%)

N/ANon-phased studies

3(8.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.5%

34 of 38 finished

Non-Completion Rate

10.5%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(34)

Terminated(4)

Other(2)

Detailed Status

Completed34

Terminated4

unknown2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

89.5%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (8.6%)

Phase 28 (22.9%)

Phase 39 (25.7%)

Phase 412 (34.3%)

N/A3 (8.6%)

Trials by Status

unknown25%

completed3485%

terminated410%

Recent Activity

0 active trials

Showing 5 of 40

terminatedphase_2

Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)

NCT04990167

terminated

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug

NCT05362487

completedphase_4

Clinical Trials (40)

Showing 20 of 40 trialsScroll for more

NCT04990167Phase 2

Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)

Terminated

NCT05362487

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug

Terminated

NCT04061161Phase 4

Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD

Completed

NCT03199976Phase 4

Efficacy of Intermittent Tiotropium in Early Childhood Wheezing

Terminated

NCT00274508Phase 3

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

Completed

NCT05113615Phase 4

Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma

Completed

NCT03083067Not Applicable

Salvational Intervention for Reducing AECOPD Under Severe Air Pollution

Completed

NCT00528996Phase 2

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

Completed

NCT00557180

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

Completed

NCT02586649Phase 2

24hr Effects of Tiotropium Bromide in Tetraplegia

Completed

NCT04137029Not Applicable

Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers

Unknown

NCT01663987Phase 4

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Completed

NCT01662986Phase 4

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Completed

NCT02172495

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

Completed

NCT00565266Phase 3

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

Completed

NCT01316900Phase 3

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Completed

NCT00157235Phase 3

Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients

Completed

NCT01566773Phase 2

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Completed

NCT00555022Phase 1

Effect of GSK1160724 In Healthy Volunteers